Scientific Name | Trade Name | Updated Section | Safety-Related Labeling Changes | Date |
---|---|---|---|---|
Docetaxel | Taxotere | 4.6. Fertility, pregnancy and lactation | Based on genetic toxicity findings, advise females of reproductive potential to use effective , contraception during treatment and for 2 months after the last dose of Docetaxel Injection. | Aug,2023 |
R-Covi | Chadox1-S [Recombinant] | 4.8 Undesirable effects | Tinnitus | Mar,2023 |
Cefprozil | Cefproz | 4.8 Undesirable effects | Seizures | Mar,2023 |
Ampicillin | Standacillin | 4.4 Special warnings and precautions for use | Severe Cutaneous Adverse Reactions | Feb,2023 |
Cadribine | Mavenclad | 4.5. Interactions with other medicinal products | Interactions with immunosuppressive medicinal product | Feb,2023 |
Clarithromycin | Klacid XL | 4.4 Special Warnings and Special Precautions for Use | Risk of Cardiovascular Events | May,2024 |